Celonic Group appoints new CEO
Celonic Group, a Swiss-based Biologics Contract Development and Manufacturing Organization (CDMO), has appointed Dr Samanta Cimitan as the Chief Executive Officer (CEO) of the Celonic Group, a subsidiary of the independent and privately owned J. Rettenmaier & Söhne Company (JRS Group).
Dr Cimitan succeeds Dr Konstantin Matentzoglu, who will step down after nine years as CEO. Dr Matentzoglu intends to remain a member of the Celonic Board.
With more than 20 years of experience working, teaching, and studying Life Sciences, Dr Cimitan is an expert in the CDMO industry, holding a deep and unique combination of scientific, commercial, and operational know-how.
Dr Cimitan joined Celonic in June 2022 as Chief Business Officer (CBO). During this time, she quickly articulated a new strategic direction for the Celonic business, solidified customer relationships, and accelerated innovation.
Prior to Celonic, Dr Cimitan was with Lonza for almost 13 years, holding several leadership positions across multiple commercial and strategy roles, including Vice President of Lonza Group Operations Strategy, developing and leading transformational programmes across R&D, Operations and Commercial functions. Dr Cimitan holds a Ph.D. in Pharmaceutical Sciences from the University of Bologna, Italy, along with a master’s degree in Industrial Chemistry.
Dr Samanta Cimitan is the new Chief Executive Officer of Celonic Group
